Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Exp Parasitol ; 261: 108749, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38593864

RESUMO

Trypanosoma cruzi (T. cruzi) causes Chagas, which is a neglected tropical disease (NTD). WHO estimates that 6 to 7 million people are infected worldwide. Current treatment is done with benznidazole (BZN), which is very toxic and effective only in the acute phase of the disease. In this work, we designed, synthesized, and characterized thirteen new phenoxyhydrazine-thiazole compounds and applied molecular docking and in vitro methods to investigate cell cytotoxicity, trypanocide activity, nitric oxide (NO) production, cell death, and immunomodulation. We observed a higher predicted affinity of the compounds for the squalene synthase and 14-alpha demethylase enzymes of T. cruzi. Moreover, the compounds displayed a higher predicted affinity for human TLR2 and TLR4, were mildly toxic in vitro for most mammalian cell types tested, and LIZ531 (IC50 2.8 µM) was highly toxic for epimastigotes, LIZ311 (IC50 8.6 µM) for trypomastigotes, and LIZ331 (IC50 1.9 µM) for amastigotes. We observed that LIZ311 (IC50 2.5 µM), LIZ431 (IC50 4.1 µM) and LIZ531 (IC50 5 µM) induced 200 µg/mL of NO and JM14 induced NO production in three different concentrations tested. The compound LIZ331 induced the production of TNF and IL-6. LIZ311 induced the secretion of TNF, IFNγ, IL-2, IL-4, IL-10, and IL-17, cell death by apoptosis, decreased acidic compartment formation, and induced changes in the mitochondrial membrane potential. Taken together, LIZ311 is a promising anti-T. cruzi compound is not toxic to mammalian cells and has increased antiparasitic activity and immunomodulatory properties.


Assuntos
Doença de Chagas , Simulação de Acoplamento Molecular , Óxido Nítrico , Tiazóis , Tripanossomicidas , Trypanosoma cruzi , Trypanosoma cruzi/efeitos dos fármacos , Tiazóis/farmacologia , Tiazóis/química , Doença de Chagas/tratamento farmacológico , Doença de Chagas/imunologia , Humanos , Animais , Camundongos , Óxido Nítrico/metabolismo , Óxido Nítrico/biossíntese , Tripanossomicidas/farmacologia , Tripanossomicidas/química , Concentração Inibidora 50 , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Hidrazinas/farmacologia , Hidrazinas/química , Citocinas/metabolismo , Camundongos Endogâmicos BALB C
2.
Am J Trop Med Hyg ; 99(6): 1541-1546, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30328408

RESUMO

Common in four continents, visceral leishmaniasis (VL) is an important but neglected disease. Human immunodeficiency virus (HIV) infection increases the risk of developing VL in people from leishmaniasis-endemic areas, with worse prognosis when there is coinfection. We conducted a cross-sectional study to determine the prevalence of HIV/VL coinfection in patients admitted in three referral hospitals for HIV/acquired immunodeficiency syndrome (AIDS) in Pernambuco, Brazil, and to compare epidemiological, clinical, and laboratory characteristics among HIV/VL coinfected and HIV mono-infected individuals. The sample consisted of HIV patients aged 18 years or more, in a period of data collection of 6 months. We performed four Leishmania tests-polymerase chain reaction (PCR), direct agglutination test, rK39, and latex agglutination test-and individuals with at least one positive test were considered coinfected. The HIV/VL coinfection prevalence we found was 16.9%. We observed large variation in prevalence according to the Leishmania test used, with low coincidence of positive tests. The most frequent symptoms found were weight loss (75.6%), fever (67.6%), and cough (55.3%). When we compared HIV/VL coinfected and HIV mono-infected groups we did not observe statistically significant differences. Low educational level (P = 0.004) and pallor (P = 0.009) were more frequent in the coinfected group. Serum albumin level was higher in coinfected individuals (P = 0.009). It is important to follow-up these individuals to understand the dynamics of VL in people living with HIV. New tests are necessary, ideally differentiating active from latent infection. Testing for VL in people with HIV is important and should be considered as part of the initial investigation in these individuals.


Assuntos
Infecções por HIV/epidemiologia , HIV/genética , Hospitalização , Leishmania/genética , Leishmaniose Visceral/epidemiologia , Adolescente , Adulto , Testes de Aglutinação , Brasil/epidemiologia , Coinfecção , Estudos Transversais , Feminino , HIV/imunologia , HIV/isolamento & purificação , Infecções por HIV/parasitologia , Infecções por HIV/fisiopatologia , Infecções por HIV/virologia , Humanos , Leishmania/imunologia , Leishmania/isolamento & purificação , Leishmaniose Visceral/parasitologia , Leishmaniose Visceral/fisiopatologia , Leishmaniose Visceral/virologia , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Prevalência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA